Clone 3.2.B8 is a monoclonal antibody targeting PDL2 (CD273), used in in vivo mouse studies to modulate immune responses by blocking the interaction between PDL2 and PD1. This blockade plays a role in enhancing T cell activation, proliferation, and cytokine production, potentially leading to increased antitumor immunity.

Key points on in vivo usage:

• Functional Grade: Clone 3.2.B8 is often provided in purified, endotoxinfree preparations suitable for direct injection into mice for experimental manipulation of immune checkpoints.
• Mechanism of Action: By binding to PDL2 on cells, it prevents the inhibitory signal that PDL2 delivers through PD1, effectively releasing the brakes on T cell activity during immune responses.
• Experimental Applications: It is primarily used to study T cell regulation, peripheral tolerance, and mechanisms of immune evasion in tumors. Common in vivo experiments include investigating how blockade of PDL2 affects:
  • T cell proliferation and activation
  • Cytokine production
  • Tumor growth and immune infiltration

Additional details:

• Species Crossreactivity: This clone recognizes both mouse and human PDL2, making it useful in models employing mouse cells and in humanized or xenograft mice.
• Application Examples: Researchers use it in synergy with other checkpoint inhibitors to dissect combinatorial effects on tumor regression and immune cell dynamics. Experimental protocols recommend following productspecific datasheets for dosing and administration.

In summary, clone 3.2.B8 is employed in vivo mainly for immune checkpoint blockade studies in mice, with its primary purpose being to modulate T cell responses by interfering with PDL2/PD1 signaling.

The 3.2.B8 antibody commonly refers to a clone specific for mouse CD273 (PDL2), used in immunological research, especially for studying immune checkpoints and T cell regulation. In published studies, 3.2.B8 is often used alongside other antibodies or proteins to provide comprehensive immunophenotyping or functional analysis.

Commonly coused antibodies/proteins with 3.2.B8 (antiPDL2) include:

• AntiCD274 (PDL1): PDL1 and PDL2 are both ligands for PD1, so studies often examine expression or blockade of both molecules together to assess immunoregulatory pathways.
• AntiPD1 (Programmed Death1): As PDL2 is a ligand for PD1, combining 3.2.B8 with antiPD1 is standard in immune checkpoint research to analyze the PD1/PDL2 pathway.
• AntiCD80 (B71) / CD86 (B72): Members of the same B7 family, often analyzed in combination to investigate costimulatory versus coinhibitory signal balance.
• AntiCD3, AntiCD4, AntiCD8: Used to phenotype T cell subsets during functional assays or flow cytometry panels involving PDL2.
• AntiMHC class II (e.g., IA/IE): As antigenpresenting cells express both MHCII and PDL2, colabeling helps define dendritic cell or macrophage subsets.

These combinations allow researchers to map out immune cell interactions, checkpoint blockade responses, and specific immune cell populations within in vivo or in vitro systems.

In summary, 3.2.B8 (antiPDL2) is most frequently used with antibodies targeting PD1, PDL1, and standard immunophenotyping markers (CD3, CD4, CD8, CD11c, MHCII), depending on the precise research application. The exact panel will vary by experiment, but these are the most recurrently reported combinations in immunological literature.

Scientific literature referencing clone 3.2.B8 primarily identifies this monoclonal antibody as a highly specific tool for recognizing PDL2 (CD273) on both mouse and human cells. The key findings from these citations include:

• CrossSpecies Reactivity: Clone 3.2.B8 binds equally well to both mouse and human PDL2, making it valuable for comparative immunological studies across species.
• Epitope Specificity: It recognizes a distinct epitope on PDL2, ensuring specific detection and potential functional blockade in assays and in vivo experiments.

Applications in Research:

• Functional Immune Studies: 3.2.B8 is used to explore PD1/PDL2 interactions, which play crucial roles in T cell regulation, immune tolerance, and lymphocyte clonal selection.
• Immune Checkpoint Investigation: By interfering with PD1/PDL2 binding, clone 3.2.B8 contributes to studies on immune checkpoint blockade, relevant for understanding mechanisms underlying cancer immunotherapy and regulation of T cell responses.

Experimental Utility:

• Versatility in Techniques: The antibody has documented utility in blocking (in vivo), flow cytometry, western blotting, and other biochemical assays, confirming its functional grade and broad applicability in immunological experiments.

No studies from the retrieved results link clone 3.2.B8 directly to infectious disease or TCR clonotype analysis, as discussed in related HIV T cell literature. Instead, its major scientific impact is enabling robust investigations into the function and therapeutic targeting of the PD1/PDL2 axis in immune modulation, including autoimmunity and oncology.

If you need details on specific experimental findings or therapeutic outcomes using clone 3.2.B8, additional targeted literature searches may be necessary.

The dosing regimens of clone 3.2.B8 across different mouse models are not directly specified in the available search results, and no published protocols are found that use clone 3.2.B8 by name. Based on typical practices for in vivo antibody dosing in mice, dosing regimens can vary significantly by mouse strain, research objective, and biological target.

For antibodies in mouse models:

• Standard doses often range from 5 to 300 µg per mouse, administered via intraperitoneal (i.p.) or intravenous (i.v.) injection, with schedules anywhere from a single dose to repeated doses every few days over several weeks.
• Mouse strain differences (like C57BL/6, ICR, Swiss, etc.) may influence dosing due to varying immune responses and pharmacokinetics. Some models respond differently to biologic agents, such as LPS, with distinct outcomes at equivalent doses.
• Common regimen examples for other clones (not 3.2.B8 specifically):
  • AntiCD3ε: 5–50 µg per mouse i.v., daily for up to 5 days
  • AntiCTLA4: 100–250 µg per mouse i.p., every ~3 days
  • AntiLy6G: 100–250 µg per mouse i.p., 3 times/week

Key factors affecting dosing choice:

• Strain sensitivity: For example, C57BL/6 mice may respond similarly to multiple doses, whereas ICR and Swiss mice may show more pronounced or attenuated effects at the same dose, seen clearly in dosing studies with LPS.
• Route and schedule: Intraperitoneal vs. intravenous administration and single vs. repeated dosing affect antibody distribution and efficacy.

If you are planning to use clone 3.2.B8 specifically:

• Start by identifying the biological target and intended effect (depletion, activation, blocking).
• Use published standard dosing for similar antibody clones as a guide (e.g., start with 100–250 µg/mouse i.p. every 3 days).
• Adjust based on mouse strain, experimental goals, and pilot data.

No direct information for clone 3.2.B8 appears in the cited literature, so adopt dosing regimens from antibodies with similar mechanisms and targets, modifying for mouse model idiosyncrasies. Always validate tolerability and efficacy in preliminary experiments.